

UBS Future of Humans USD F-UKdist


Fund Fact Sheet

UBS Funds for discretionary mandates > UBS Equity Funds

Fund description

- An actively managed multi-manager global equity fund that invests in companies exposed to the global trends toward an aging population, the growth in population and increasing urbanization.
- These aspects can comprise any sectors, countries and company capitalisations in order to benefit from disruptive developments in society, resources and technology, with a focus on longevity, education, healthcare and consumer preferences.
- The MSCI ACWI Net Total Return index is used in marketing materials for performance comparison purposes only. The fund is not constrained by this benchmark index.

Performance (basis USD, net of fees)¹



Past performance is not a reliable indicator of future results.

Name of fund	Multi Manager Access II - Future of Humans
Share class	Multi Manager Access II - Future of Humans USD F-UKdist
ISIN	LU2213665578
Securities no.	56 355 300
Bloomberg	MFOHUFU LX
Currency of fund / share class	USD/USD
Launch date	19.10.2020
Issue/redemption	daily
Swing pricing	yes
Accounting year end	31 July
Benchmark	MSCI ACWI Net Total Return index
Distribution	August
Last distribution 21.08.2023	USD 0.28
Management fee p.a.	0.64%
Total expense ratio (TER) p.a. ¹	0.81%
Name of the Management Company	UBS Fund Management (Luxembourg) S.A., Luxembourg
Fund domicile	Luxembourg
SFDR Classification	Art.6
Overall Morningstar Rating	★★

¹ as at 31.07.2023

in %	2020	2021	2022	2023	2024 YTD ²	LTD ³ 3 years	Ø p.a. 3 years
Fund (USD)	n.a.	5.55	-25.74	10.90	-0.93	-6.43	-14.31
Ref. Index ⁴	n.a.	18.54	-18.36	22.20	0.59	33.16	19.49

The performance shown does not take account of any commissions, entry or exit charges.

¹ These figures refer to the past. **If the currency of a financial product, financial service or its costs is different from your reference currency, the return and/or costs can increase or decrease as a result of currency fluctuations.** Source for all data and chart (if not indicated otherwise): UBS Asset Management.

² YTD: year-to-date (since beginning of the year)

³ LTD: launch-to-date

⁴ Reference Index in currency of share class (without costs)

Fund statistics

Net asset value (USD, 31.01.2024)	92.59
Last 12 months (USD) – high	93.97
– low	80.85
Total fund assets (USD m)	146.64
Share class assets (USD m)	0.03

	3 years	5 years
Beta	0.91	n.a.
Volatility ¹		
– Fund	16.22%	n.a.
– Benchmark	16.52%	n.a.
Sharpe ratio	-0.47	n.a.
Risk free rate	2.54%	n.a.

¹ Annualised standard deviation

For more information

Internet: www.ubs.com/luxembourg/funds
Contact your client advisor

UBS Future of Humans USD F-UKdist

Sector exposure (%)

	Fund	Index
Health Care	49.76	11.43
Consumer Discretionary	15.00	10.74
Financials	10.83	15.99
Information Technology	9.36	23.52
Communication Services	6.50	7.51
Industrials	6.00	10.54
Real Estate	1.55	2.27
Consumer Staples	0.89	6.72
Materials	0.00	4.25
Others	0.11	7.03

Market exposure (%)

	Fund	Deviation from index
United States	69.15	+6.0
China	3.48	+1.0
France	3.29	+0.4
Japan	3.21	-2.4
Denmark	2.98	+2.1
United Kingdom	2.81	-0.7
Switzerland	2.79	+0.4
Ireland	2.09	+2.0
Hong Kong	1.50	+1.0
Netherlands	1.49	+0.3
Others	7.21	-10.2

Benefits

Benefit from developments driven by the meta themes education, healthcare and changing consumer preferences. Harnesses the dedicated capabilities of leading thematic portfolio managers, most of whom are not accessible via public funds.

A focus on attractively valued companies with strong links to the respective themes.

The structure allows for the addition/removal of managers as well as portfolio optimization.

10 largest equity positions (%)

	Fund	Index
Eli Lilly & Co	2.77	0.77
Boston Scientific Corp	2.70	0.14
Novo Nordisk A/S	2.62	0.54
UnitedHealth Group Inc	2.50	0.70
Booking Holdings Inc	2.00	0.19
Danaher Corp	2.00	0.25
Abbott Laboratories	1.74	0.29
Amazon.com Inc	1.65	2.13
Meta Platforms Inc	1.65	1.28
AstraZeneca PLC	1.63	0.31

Investment managers and Strategy

Invesco - Consumer preferences	20.72
Newton - Longevity	42.94
UBS AM - Health	13.60
Wellington - Education	22.74

Risks

A new fund with no track record, notwithstanding the investment history of the portfolio managers.

An equity fund with exposure to emerging economies and to small, growing and innovative companies which can result in significant fluctuations in value, particularly in the short term. The thematic focus may lead to concentrations in a specific sector.

The performance of actively managed funds may deviate significantly from the referenced index.

The fund can use derivatives, which may result in additional counterparty and liquidity risks.

UBS Future of Humans USD F-UKdist

Glossary of key terms

Benchmark

Index against which an investment fund's performance is measured. Also called a reference index.

Beta

A measure of risk which indicates the sensitivity of an investment, such as an investment fund, to fluctuations in the market, as represented by the relevant benchmark. For example, a beta of 1.2 tells us that the value of an investment fund can be expected to change by 12% if the market is forecast to move by 10%. The relation is based on historical data and is only an approximation. However, the closer the correlation between the benchmark and the investment fund, the better this approximation.

Correlation

A measure of the degree to which the price trends of various investment categories or instruments move in the same direction. The correlation quantifies the strength of the relationship as a figure between -1 and +1. The closer the coefficient is to 1, the stronger the correlation. If the coefficient is -1, the investments and the benchmark move in opposite directions. If the value is 0, there is no correlation.

Duration

The duration represents the length of time for which capital is "tied up" in a bond investment. In contrast to residual maturity calculations, the concept of duration takes account of the time structure of returning cash flows (such as coupon repayments). The average duration of the portfolio is derived from the weighted average duration of the individual securities. The "modified duration" is derived from the duration and provides a measure of the risk with which the

sensitivity of bonds or bond portfolios to interest-rate changes can be estimated. A 1% increase (decrease) in the interest level accordingly produces a percentage fall (rise) in the price in proportion to the modified duration. For example: the modified duration of a bond fund is 4.5, the theoretical yield to maturity is 5.3%. If the theoretical yield to maturity drops in the example by 1% to 4.3% due to the decline in interest rates, the fund price increases by around 4.5%. For bond and asset allocation funds, the duration is given for all fixed-income instruments.

Investment grade

Term used to denote securities with ratings of between BBB and AAA, indicating that their credit quality is satisfactory or good.

Sharpe ratio

The Sharpe ratio expresses how much higher (or lower) a return an investor can expect compared to the risk-free rate of interest (e.g. interest rates on savings accounts) per unit of risk (volatility). The risk-free rate of interest varies from currency to currency.

Tracking error

Measure of the deviation of the return of a fund compared to the return of a benchmark over a fixed period of time. Expressed as a percentage. The more passively the investment fund is managed, the smaller the tracking error.

Volatility

In portfolio theory the risk of an investment is measured by the amount of volatility. Risk and return are directly related: Markowitz's portfolio theory posits that a higher return can only be obtained with a higher risk.

Please note the following information about the Morningstar Ratings: © 2023 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.

Please note that additional fees (e.g. entry or exit fees) may be charged. Please refer to your financial adviser for more details. Investors should read the Key Information Document, Prospectus and any applicable local offering document prior to investing and to get complete information of the risks. Investors are acquiring units or shares in a fund, and not in a given underlying asset such as building or shares of a company. For a definition of financial terms refer to the glossary available at www.ubs.com/am-glossary.

For marketing and information purposes by UBS. UBS funds under Luxembourg law. Arrangements for marketing fund units mentioned in this document may be terminated at the initiative of the management company of the fund(s). Representative in Switzerland for UBS funds established under foreign law: UBS Fund Management (Switzerland) AG, P.O. Box, CH-4002 Basel. Paying agent: UBS Switzerland AG, Bahnhofstrasse 45, CH-8001 Zurich. Prospectuses, key information document, the articles of association or the management regulations as well as annual and semi-annual reports of UBS funds are available in a language required by the local applicable law free of charge from UBS Asset Management Switzerland AG, c/o UBS AG, Bahnhofstrasse 45, 8001 Zürich, Switzerland or from UBS Fund Management (Switzerland) AG, P.O. Box, CH-4002 Basel. The product described herein aligns to Article 6 Regulation (EU) 2019/2088 on sustainability-related disclosures in the financial services sector. Information on sustainability-related aspects pursuant to that regulation can be found on www.ubs.com/funds. The benchmark is the intellectual property of the respective index provider. The fund or the share class is neither sponsored nor endorsed by the index provider. The fund prospectus or supplemental prospectus contains the full disclaimer. Before investing in a product please read the latest prospectus and key information document carefully and thoroughly. Any decision to invest should take into account all the characteristics or objectives of the fund as described in its prospectus, or similar legal documentation. Investors are acquiring units or shares in a fund, and not in a given underlying asset such as building or shares of a company. Members of the UBS Group may have a position in and may make a purchase and / or sale of any of the securities or other financial instruments mentioned in this document. Units of UBS funds mentioned herein may not be eligible for sale in all jurisdictions or to certain categories of investors and may not be offered, sold or delivered in the United States. The information mentioned herein is not intended to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. Past performance is not a reliable indicator of future results. The calculated performance takes all costs on the fund level into consideration (ongoing costs). The entry and exit costs, which would have a negative impact on the performance, are not taken into consideration. If whole or part of the total costs to be paid is different from your reference currency, the costs may increase or decrease as a result of currency and exchange rate fluctuations. Commissions and costs have a negative impact on the investment and on the expected returns. If the currency of a financial product or financial service is different from your reference currency, the return can increase or decrease as a result of currency and exchange rate fluctuations. This information pays no regard to the specific or future investment objectives, financial or tax situation or particular needs of any specific recipient. Future performance is subject to taxation which depends on the personal situation of each investor and which may change in the future. The details and opinions contained in this document are provided by UBS without any guarantee or warranty and are for the recipient's personal use and information purposes only. This document may not be reproduced, redistributed or republished for any purpose without the written permission of UBS Asset Management Switzerland AG or a local affiliated company. Source for all data and charts (if not indicated otherwise): UBS Asset Management. A summary of investor rights in English can be found online at www.ubs.com/funds. More explanations of financial terms can be found at www.ubs.com/am-glossary.

© UBS 2024. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.